Lorlatinib After Five Years: TP53 and EML4::ALK Variant 3 Refine Prognosis but Do Not Define Benefit in ALK-Positive NSCLC
Long-term follow-up from the global phase II lorlatinib study provides a more mature view of how tumor biology…
Browsing Category